Directorate Change
CFO Emily Bertram leaves 30 June 2026; interim CFO engaged while permanent replacement is sought.
Select text to share a quote on X · sign in to keep highlights & notes in your SBTX notes
25 June 2026 - SkinBioTherapeutics plc, (AIM: SBTX), the life science business focused on skin health, announces that Emily Bertram, Chief Financial Officer, has decided to leave the business on 30 June 2026.
During her tenure, Emily has demonstrated the highest standards of professionalism, integrity and leadership, and has made a significant contribution to the Company's financial stewardship and governance. She was instrumental in identifying and escalating the issues to the Board regarding the former CEO's conduct and she has worked closely with Alyson Levett and Rachel Parsonage to ensure the business continues to operate as usual. She is ensuring an orderly handover before her departure.
The Company has engaged an Interim CFO, on a non-Board basis, who brings extensive experience as a Chartered Accountant and AIM-listed plc CFO, including a demonstrable track record in strengthening financial controls, corporate governance and reporting standards. The process for hiring a new permanent CFO is underway.
The Board wishes to express its gratitude for Emily's dedication and commitment, and extends its best wishes for her future career.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.